Daniel Vasella - 2009 CEO Pay
Daniel Vasella - Novartis
Total Compensation: $17.8 million
Details: In his last year as Novartis' chairman and chief executive, Vasella received a base salary of $2.6 million in 2009, plus short-term incentives of about $99,000, long-term incentives totaling $1.6 million and benefits of about $385,000. He owned 2,924,114 shares in the company. After 14 years as Novartis' CEO, Vasella announced he was stepping down in January. He was replaced by Novartis pharma chief Joe Jimenez (photo).
Novartis News:
Vasella, Jimenez share the limelight
Novartis chief steps aside for Jimenez
New Novartis chief talks productivity
Novartis CEO goes on a 'decluttering' drive
Falling Novartis stock deflates bid for Alcon shares
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: